You just read:

Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019

News provided by

Actinium Pharmaceuticals, Inc.

Nov 06, 2019, 09:15 ET